DRUG
atosiban
Atosiban was administered as a 6.75mg IV bolus dose 30 minutes prior to embryo transfer followed by a 1-hour IV infusion at dose of 18 mg/h then a 2-hour IV infusion at 6 mg/h.
Atosiban Improves Implantation and Pregnancy Rates in Patients With Repeated Implantation Failure
Status
Completed
Phase
Not applicable
Enrollment
71
Locations
1
Results
Not posted
Publications
1
Study summary
What the protocol is testing.
Atosiban, administered at embryo transfer, can improve the implantation rate and the clinical pregnancy rate in patients with repeated implantation failure undergoing IVF-ET (in-vitro fertilization and embryo transfer).
Full detailed description
Atosiban is a mixed oxytocin and vasopressin V1A receptor antagonist.Combined antagonism at oxytocin and vasopressin V1A receptors reduces uterine contractions with a corresponding decrease in intrauterine production of prostaglandin F2alpha and improved uterine blood supply. These effects are of potential benefit for implantation support during IVF-ET cycles.
Interventions
Treatment arms and agents.
Timeline
From registration to results.
First posted
Dec 16, 2011
Study start
Mar 2011
Primary completion
Aug 2011
Study completion
Sep 2011
Results posted
Not reported
Registry updated
Dec 20, 2011
Outcomes
What the study measures.
Primary outcomes
Clinical pregnancy
Time frame · 5 weeks after intervention
Secondary outcomes
Not reported in the indexed record.
Eligibility
Who can take part.
- Minimum age
- Not reported
- Maximum age
- Not reported
- Sex
- FEMALE
- Healthy volunteers
- No
Inclusion Criteria: * had repeated implantation failure * have at least 1 good quality embryo for transfer Exclusion Criteria: * uterine abnormalities that could compromise the implantation process (e.g. fibroids, endometrial polyp, bicornuate uterus, adhesion of uterine cavity)
Study locations
1 registered sites.
Vietnam. Showing up to 24 locations stored in the fast local snapshot.
IVFAS, An Sinh Hospital
Ho Chi Minh City, Ho Chi Minh, Vietnam
Publications
Results and literature.
Related trials
More studies on Atosiban.
NCT IDStudyPhase / statusEnrollmentUpdated
Atosiban in Women With Previous Implantation Failure and Abnormal Uterine Contractions
Northwest Women's and Children's Hospital, Xi'an, Shaanxi · Infertility
Not applicable
Recruiting
792
2025-12
The Effect of Oral Oxytocin and Atosiban on Top-down Attention ( OTAtosiban )
University of Electronic Science and Technology of China · Healthy Adult Male
Early Phase 1
Recruiting
250
2025-09
The Effect of Oral Oxytocin and Atosiban on Social Attention
University of Electronic Science and Technology of China · Healhty
Early Phase 1
Recruiting
250
2025-07
Perioperative Use of Atosiban for Ultrasound-indicated Cerclage to Reduce Spontaneous Preterm Birth(sPTB)
Children's Hospital of Chongqing Medical University · Cervical Cerclage · Premature Birth
Not applicable
Completed
334
2025-05
Atosiban Versus Placebo in the Treatment of Late Threatened Pre-term Birth
Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) · Preterm Birth
Phase 4
Completed
760
2024-07
In Utero Repair of Myelomeningocele: Atosiban Versus Terbutaline
University of Sao Paulo General Hospital · Myelomeningocele · Terbutaline Adverse Reaction
Not applicable
Completed
25
2022-06
The Effect of Selective Oxytocin Receptor Inhibitors on Endometriosis-related Pain
Radboud University Medical Center · Endometriosis
Phase 2
Unknown
10
2022-05
Role of Atosiban in Recurrent Implantation Failure
Al Baraka Fertility Hospital · Recurrent Implantation Failure
Not applicable
Unknown
150
2021-09
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.